MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
|Podcasts|October 13, 2018
Podcast: This Week in Managed Care—DOJ Approves CVS–Aetna Merger and Other Health News
Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Advertisement
Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
This week, the top managed care news included the Department of Justice giving the green light for the CVS—Aetna merger; premiums for employer insurance plans are on the rise; and the new North American trade deal includes protections for drug makers that will hurt biosimilars.
You may need to log in to the website to access this podcast.
iTunes:
TuneIn:
Stitcher:
Listen above or through one of these podcast services:
Read more about the stories in this podcast:
Advertisement
Related to this article
This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Patch testing in Malaysia finds contact dermatitis drivers in chronic hand eczema—nickel and fragrance allergy lead, while cosmetics raise polysensitization risk.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
3
VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
4
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
5